The goal of the collaboration is to give researchers better access to deidentified medical history data and associated specimens. The electronic data sharing between the parties eliminates the manual transcription of medical record data, resulting in a lower likelihood of data procurement delays, gaps, and errors.

The agreement will allow researchers to access both positive and negative SARS-CoV-2 swabs through the iSpecimen Marketplace for use in developing treatments and vaccines. The anonymous test samples come from DPS and DHIN, iSpecimen said.

"There's great demand for COVID-19 treatments and vaccines, and there's no reason researchers should wait weeks or even months for specimens before getting to work," founder and CEO Dr. Christopher Ianelli, Ph.D, said in an iSpecimen statement. "Our mission is to simplify not only the collection of samples, but all the processes around the procurement, including data annotation, contracting, compliance, and delivery."

New Zealand to purchase 10.7M doses of Novavax COVID-19 vaccine
The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

Valneva begins clinical trials for inactivated, adjuvanted COVID-19 vaccine
Valneva has begun a phase I/II clinical trial to study its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Genes provide new targets for COVID-19 therapies
Genes associated with antiviral immunity and lung inflammation have been tied to severe cases of COVID-19 in a new genome-wide analysis conducted in the...

AbbVie licenses anti-COVID-19 antibody for clinical development
Harbour BioMed and Utrecht University have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. AbbVie has initiated a phase...